If you took Truvada, Viread, or another tenofovir disoproxil fumarate (TDF) medication for HIV treatment or prevention and later suffered bone density loss or kidney damage, you may qualify for compensation.
Truvada, Viread, and related medications built on tenofovir disoproxil fumarate (TDF) have been widely prescribed for years to treat and prevent HIV. Lawsuits allege the manufacturer knew TDF could cause significant bone density loss and kidney damage, and had developed a chemically related but safer formulation — tenofovir alafenamide (TAF) — years before bringing it to market, delaying the safer alternative in order to keep profiting from TDF sales before patent protection expired.
The litigation runs on two separate tracks. A federal settlement reached in 2024 resolved thousands of the earliest-filed cases in the multidistrict litigation. Separately, more than 24,000 additional cases remain active in California state court, where a pending state supreme court decision is expected to shape how the remaining claims move forward.
Here's what happens after you reach out:
A short set of free eligibility questions about your situation — takes about two minutes.
Our network reviews your answers against current qualifying criteria and reaches out if you may qualify.
You decide whether to move forward. There's never a cost to check your eligibility.
With one wave of federal cases resolved through a 2024 settlement, the litigation's center of gravity has shifted to California state court, where tens of thousands of cases are awaiting a pending state supreme court decision on a key legal question in the case. That ruling, expected sometime in 2026, is likely to influence how the remaining claims are handled going forward.
Get updates on Truvada/Viread, plus other case types we cover.
We'll keep you updated on Truvada/Viread and other case types.